Selected research
Industry Research
Influenza Drugs Industry Research Report 2026
Market perspective
The global Influenza Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Influenza Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Influenza Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Influenza Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Influenza Drugs include Novartis, Roche, Eli Lilly, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca, Serum Institute of India and Seqirus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Influenza Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Influenza Drugs Market by Company
Novartis
Roche
Eli Lilly
Pfizer
GlaxoSmithKline
Bayer
AstraZeneca
Serum Institute of India
Seqirus
Sanofi Pasteur
Protein Sciences Corporation
Emergent Biosolutions
Celgene
Bristol-Myers Squibb]
BioCryst Pharmaceuticals
Alvogen
Influenza Drugs Segment by Type
Oseltamivir Phosphate
Peramivir
Zanamivir
Other Influenza Drugs
Influenza Drugs Segment by Application
Adults
Chidren
Influenza Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Influenza Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Influenza Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Influenza Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Influenza Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oseltamivir Phosphate
- Peramivir
- Zanamivir
- Other Influenza Drugs
Applications
- Adults
- Chidren
Companies covered
- Novartis
- Roche
- Eli Lilly
- Pfizer
- GlaxoSmithKline
- Bayer
- AstraZeneca
- Serum Institute of India
- Seqirus
- Sanofi Pasteur
- Protein Sciences Corporation
- Emergent Biosolutions
- Celgene
- Bristol-Myers Squibb]
- BioCryst Pharmaceuticals
- Alvogen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Influenza Drugs Market Size (2021-2032)
- 2.2.2 Global Influenza Drugs Sales (2021-2032)
- 2.2.3 Global Influenza Drugs Market Average Price (2021-2032)
- 2.3 Influenza Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oseltamivir Phosphate
- 2.3.3 Peramivir
- 2.3.4 Zanamivir
- 2.3.5 Other Influenza Drugs
- 2.4 Influenza Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Chidren
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Influenza Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Influenza Drugs Sales (K Tons) of Manufacturers (2021-2026)
- 3.3 Global Influenza Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Influenza Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Influenza Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Influenza Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Influenza Drugs, Product Type & Application
- 3.8 Global Manufacturers of Influenza Drugs, Established Date
- 3.9 Global Influenza Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis Influenza Drugs Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Roche
- 4.2.1 Roche Company Information
- 4.2.2 Roche Business Overview
- 4.2.3 Roche Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Roche Influenza Drugs Product Portfolio
- 4.2.5 Roche Recent Developments
- 4.3 Eli Lilly
- 4.3.1 Eli Lilly Company Information
- 4.3.2 Eli Lilly Business Overview
- 4.3.3 Eli Lilly Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly Influenza Drugs Product Portfolio
- 4.3.5 Eli Lilly Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Influenza Drugs Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 GlaxoSmithKline
- 4.5.1 GlaxoSmithKline Company Information
- 4.5.2 GlaxoSmithKline Business Overview
- 4.5.3 GlaxoSmithKline Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GlaxoSmithKline Influenza Drugs Product Portfolio
- 4.5.5 GlaxoSmithKline Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Influenza Drugs Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 AstraZeneca
- 4.7.1 AstraZeneca Company Information
- 4.7.2 AstraZeneca Business Overview
- 4.7.3 AstraZeneca Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AstraZeneca Influenza Drugs Product Portfolio
- 4.7.5 AstraZeneca Recent Developments
- 4.8 Serum Institute of India
- 4.8.1 Serum Institute of India Company Information
- 4.8.2 Serum Institute of India Business Overview
- 4.8.3 Serum Institute of India Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Serum Institute of India Influenza Drugs Product Portfolio
- 4.8.5 Serum Institute of India Recent Developments
- 4.9 Seqirus
- 4.9.1 Seqirus Company Information
- 4.9.2 Seqirus Business Overview
- 4.9.3 Seqirus Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Seqirus Influenza Drugs Product Portfolio
- 4.9.5 Seqirus Recent Developments
- 4.10 Sanofi Pasteur
- 4.10.1 Sanofi Pasteur Company Information
- 4.10.2 Sanofi Pasteur Business Overview
- 4.10.3 Sanofi Pasteur Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sanofi Pasteur Influenza Drugs Product Portfolio
- 4.10.5 Sanofi Pasteur Recent Developments
- 4.11 Protein Sciences Corporation
- 4.11.1 Protein Sciences Corporation Company Information
- 4.11.2 Protein Sciences Corporation Business Overview
- 4.11.3 Protein Sciences Corporation Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Protein Sciences Corporation Influenza Drugs Product Portfolio
- 4.11.5 Protein Sciences Corporation Recent Developments
- 4.12 Emergent Biosolutions
- 4.12.1 Emergent Biosolutions Company Information
- 4.12.2 Emergent Biosolutions Business Overview
- 4.12.3 Emergent Biosolutions Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Emergent Biosolutions Influenza Drugs Product Portfolio
- 4.12.5 Emergent Biosolutions Recent Developments
- 4.13 Celgene
- 4.13.1 Celgene Company Information
- 4.13.2 Celgene Business Overview
- 4.13.3 Celgene Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Celgene Influenza Drugs Product Portfolio
- 4.13.5 Celgene Recent Developments
- 4.14 Bristol-Myers Squibb]
- 4.14.1 Bristol-Myers Squibb] Company Information
- 4.14.2 Bristol-Myers Squibb] Business Overview
- 4.14.3 Bristol-Myers Squibb] Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Bristol-Myers Squibb] Influenza Drugs Product Portfolio
- 4.14.5 Bristol-Myers Squibb] Recent Developments
- 4.15 BioCryst Pharmaceuticals
- 4.15.1 BioCryst Pharmaceuticals Company Information
- 4.15.2 BioCryst Pharmaceuticals Business Overview
- 4.15.3 BioCryst Pharmaceuticals Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 BioCryst Pharmaceuticals Influenza Drugs Product Portfolio
- 4.15.5 BioCryst Pharmaceuticals Recent Developments
- 4.16 Alvogen
- 4.16.1 Alvogen Company Information
- 4.16.2 Alvogen Business Overview
- 4.16.3 Alvogen Influenza Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Alvogen Influenza Drugs Product Portfolio
- 4.16.5 Alvogen Recent Developments
5 Global Influenza Drugs Market Scenario by Region
- 5.1 Global Influenza Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Influenza Drugs Sales by Region: 2021-2032
- 5.2.1 Global Influenza Drugs Sales by Region: 2021-2026
- 5.2.2 Global Influenza Drugs Sales by Region: 2027-2032
- 5.3 Global Influenza Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Influenza Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Influenza Drugs Revenue by Region: 2027-2032
- 5.4 North America Influenza Drugs Market Facts & Figures by Country
- 5.4.1 North America Influenza Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Influenza Drugs Sales by Country (2021-2032)
- 5.4.3 North America Influenza Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Influenza Drugs Market Facts & Figures by Country
- 5.5.1 Europe Influenza Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Influenza Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Influenza Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Influenza Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Influenza Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Influenza Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Influenza Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Influenza Drugs Market Facts & Figures by Country
- 5.7.1 South America Influenza Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Influenza Drugs Sales by Country (2021-2032)
- 5.7.3 South America Influenza Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Influenza Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Influenza Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Influenza Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Influenza Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Influenza Drugs Sales by Type (2021-2032)
- 6.1.1 Global Influenza Drugs Sales by Type (2021-2032) & (K Tons)
- 6.1.2 Global Influenza Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Influenza Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Influenza Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Influenza Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Influenza Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Influenza Drugs Sales by Application (2021-2032)
- 7.1.1 Global Influenza Drugs Sales by Application (2021-2032) & (K Tons)
- 7.1.2 Global Influenza Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Influenza Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Influenza Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Influenza Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Influenza Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Influenza Drugs Value Chain Analysis
- 8.1.1 Influenza Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Influenza Drugs Production Mode & Process
- 8.2 Influenza Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Influenza Drugs Distributors
- 8.2.3 Influenza Drugs Customers
9 Global Influenza Drugs Analyzing Market Dynamics
- 9.1 Influenza Drugs Industry Trends
- 9.2 Influenza Drugs Industry Drivers
- 9.3 Influenza Drugs Industry Opportunities and Challenges
- 9.4 Influenza Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst